Kos Biotechnology Partners Closes $123 Million Inaugural Life Sciences Fund, Marking Greece's Largest VC Launch

Kos Biotechnology Partners (搜索)搜索该词条, a global life sciences investment firm with offices in New York and Athens, Greece, announced the third closing of its inaugural global life sciences fund, bringing total capital commitments to $123 million (€106 million). The milestone, reached just months after the fund's initial launch in December 2025, establishes Kos as the first life sciences-dedicated investment fund in Greece and marks the largest venture capital fund launch in the country's history.

The fund has secured backing from a syndicate of prominent institutional investors, including lead investor Hellenic Development Bank of Investments (搜索)搜索该词条 (HDBI), alongside global family offices. The firm noted that this launch also stands as one of the largest first-time life sciences VC launches in Europe.

"The convergence of novel biology with data science and advanced computing is creating unprecedented opportunities to cure complex diseases," said Dr. Simos Simeonidis, Co-Founder and Managing Partner. "Our mission is to back exceptional entrepreneurs redefining the standard of care by leveraging our proprietary international network to connect US drug development know-how with specialized scientific talent."

Leadership and Expertise

Kos was founded by Dr. Simos Simeonidis and Alex Tzoukas, combining institutional investing expertise with deep scientific domain knowledge. Dr. Simeonidis brings biomedical training from Columbia and Harvard Medical Schools, alongside over a decade of Wall Street experience analyzing biotechnology companies at Morgan Stanley, Cowen & Co, and RBC, with a strong private and public investment track record at Sarissa Capital and Ally Bridge Group.

Alex Tzoukas contributes more than a decade of investment banking and private equity experience in the healthcare sector, drawing from his tenure at Deutsche Bank, MTS Health Partners, and Gurnet Point Capital. Nikos Kostaras joins as the third partner, adding operational and strategic expertise from his most recent role as Greece's country head at IQVIA查看公司主页.

"Securing our third closing at $123 million in just a few months validates our cross-border thesis and underscores the immense potential of bridging US scientific innovation and drug development expertise with Europe's advancing life sciences ecosystem," added Alex Tzoukas. "Our ability to invest flexibly across all growth stages ensures Kos can function as a committed, long-term operational partner to innovators transforming human health."

Investment Strategy

The firm deploys strategic capital flexibly across all stages of development, from company formation through Series C, targeting high-impact investments in three core life sciences subsectors. In biotech and novel therapeutics, Kos backs first-in-class or best-in-class modalities addressing critical unmet medical needs. Its pharma services focus supports next-generation contract research, development, and manufacturing platforms to accelerate drug discovery. The tech-enabled technologies pillar capitalizes on computational tools, data infrastructure, and machine learning models that de-risk clinical development.

Kos leverages an advisory network comprising prominent industry leaders drawn from the Greek diaspora in the United States, bringing together scientific minds, clinical experts, and corporate biopharma executives to help portfolio companies scale globally.

Operational Momentum

Demonstrating strong operational momentum, Kos has already completed its first two investments. These include leading the recent financing round for tech-enabled pharma services provider Epikast (搜索)搜索该词条, alongside a strategic investment in a San Francisco-based biotechnology company to be announced soon. Multiple additional investments are slated for completion later this year.